Eden Biologics finalizes sale of CDMO assets to Bora 18-Jul-2022 By Jane Byrne Eden Biologics reports that it has completed the divestment of its CDMO business assets to Bora Pharmaceuticals.
Bora Pharmaceuticals acquires CDMO assets from Eden Biologics 12-May-2022 By Jane Byrne Taiwan based CDMO, Bora Pharmaceuticals, says the acquisition of CDMO assets from local player, Eden Biologics, will help it build a presence in large-molecule contract drug development and manufacturing.
